Published in final edited form as:

J Am Acad Dermatol. 2019 February ; 80(2): 538–549. doi:10.1016/j.jaad.2018.09.055.

Approaches to limit systemic antibiotic use in acne: Systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments.

John S. Barbieri, MD, MBA^{#1}, Natalie Spaccarelli, MD^{#1}, David J. Margolis, MD, PhD^{1,2}, and William D. James, MD¹

¹Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA

²Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA

These authors contributed equally to this work.

Abstract

Acne is one of the most common diseases worldwide and affects approximately 50 million individuals in the United States. Oral antibiotics are the most common systemic agent prescribed for the treatment of acne. However, their use may be associated with a variety of adverse outcomes including bacterial resistance and disruption of the microbiome. As a result, multiple treatment guidelines call for limiting the use of oral antibiotics in the treatment of acne, although actual prescribing often does not follow these guidelines. In this review, the rationale for concerns regarding the use of oral antibiotics for the management of acne is reviewed. In addition, we will discuss our approach to complying with the intent of the guidelines, with a focus on novel topical agents, dietary modification, laser and light-based modalities, and systemic medications such as spironolactone, combined oral contraceptives, and oral isotretinoin.

Antibiotic resistance is a growing problem across medicine and rates of antibiotic resistance among isolates of *Cutibacterium* (formerly *Propionibacterium*) *acnes* have been rising, including to tetracycline-class antibiotics.^{1–4} In addition to resistance among *C. acnes*, the use of oral antibiotics is associated with disruption of the normal flora, bacterial resistance among other organisms, and increased rates of upper respiratory infection and pharyngitis.^{5–8} Antibiotic use may also be associated with inflammatory bowel disease and collagen vascular disease.^{7–16} Finally, there may be an association between the use of oral tetracycline-class antibiotics and risk of breast and colon cancer.^{17,18} As a result, there have

Corresponding author: John Barbieri, 2 Maloney, 3600 Spruce Street, Philadelphia, PA 19104, USA, Phone: 215-662-2737; Fax: 215-349-8839, john.barbieri@uphs.upenn.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest Disclosure: The authors have no conflict of interest to declare.

This work has not been previously published or presented. Reprints are not available.

been calls throughout medicine to decrease overuse of antibiotics and multiple recent acne guidelines recommend limiting their use.^{19–25} However, in clinical practice, antibiotics are the most frequently prescribed systemic therapy for acne and are often used for longer durations than recommended in the guidelines.^{26–29} In fact, dermatologists prescribe more antibiotics per provider than any other specialty.³⁰ In this article, we will discuss alternative approaches to limit antibiotic use in the treatment of acne.

SPIRONOLACTONE

Given the crucial role of hormones in the pathogenesis of acne, therapies with antiandrogenic or antisebogenic properties are mechanistically enticing options.^{31–35} Spironolactone is a synthetic 17-lactone steroid that has antagonistic effects on the androgen and progesterone receptors. Although its original clinical application was as a potassium-sparing diuretic, due to its impact on sebum production through inhibition of the androgen receptor on sebocytes, spironolactone has been used off-label in the treatment of acne for over 30 years.^{36–44} It is also may reduce synthesis of androgen precursors in the adrenal glands.^{45,46}

While a 2009 Cochrane review found that randomized trials evaluating spironolactone for the treatment of acne were too scarce and small to support its effectiveness, there have since been multiple large, retrospective, observational studies of several hundred patients supporting its effectiveness (Table 1).^{47–54} Although use of spironolactone has increased substantially in recent years, oral antibiotics are still prescribed three to five times more frequently among women with acne.²⁷ As a result, increased use of spironolactone may represent an opportunity to improve antimicrobial stewardship and outcomes in patients with acne. Finally, it is important to note that spironolactone may be effective for acne in women of all ages and its use should not be limited only to adult women or women with prominent acne on the lower face or acne that flares with their menstrual cycle.^{49,52,55} In our practice, the starting dose is typically 100mg/day in the evening (Table 2).³⁵ Doses up to 200mg/day can be used, however, side-effects increase with higher doses.^{35,44,48} Several months of treatment is typically required to reach the full effectiveness of treatment.

Adverse effects and monitoring

The most common side-effect in patients taking spironolactone is menstrual irregularities, which occur in 15–30% of patients. This side-effect is dose dependent, with a relative risk of 4.12 (95% CI 3.27–5.19) in women receiving a dose of 200mg/day compared to those receiving lower doses. The concomitant use of a COC or hormonal intrauterine device can minimize the incidence of this side effect.^{44,56} Other side-effects include breast tenderness (3–5%), dizziness (3–4%), nausea (2–4%), headache (2%), polyuria (1–2%), and fatigue (1–2%).⁴⁴ Spironolactone is pregnancy category C. However, when administered in high doses to rats it has been found to cause feminization of the male fetus and there are no well-controlled human studies of its use in pregnancy.⁵⁷ Therefore, patients should be counseled to avoid becoming pregnant while on spironolactone.

Since spironolactone is a potassium-sparing diuretic, hyperkalemia is a potential complication, which has been observed at high-doses in patients with renal insufficiency or

severe heart failure.⁵⁸ However, in young healthy women being treated for acne who do not have heart disease, hypertension, or renal disease, and who are not taking potentially interacting medications such as angiotensin converting enzyme inhibitors, there is no evidence of increased rates of hyperkalemia when compared to control patients not taking spironolactone.⁵⁹ In addition, spironolactone appears safe in patients who are receiving concomitant therapy with a drospirenone containing COC.^{55,60} As a result, potassium monitoring in young, healthy women is not required, but should be followed in the uncommon woman with acne who also has risk factors for hyperkalemia.¹⁹

Due to evidence of tumorigenicity in animal studies using doses over 100 times greater than those used in clinical practice, spironolactone has a black box warning recommending against off-label and unnecessary use of spironolactone.⁵⁸ However, several large cohort studies with over 30 million person-years of combined follow-up have not confirmed such a risk when used in typical clinical practice.^{61–64} In a study of women treated for acne with spironolactone, which included 200 person-years of spironolactone exposure and 506 person-years of follow-up, no cases of serious illnesses attributable to spironolactone were observed.⁶¹ In our practice, for patients with a family history of breast or ovarian cancer, we will still consider its use after a thorough discussion of the black box warning.

ORAL CONTRACEPTIVES

Combined oral contraceptives (COCs, Table 3) containing estrogen and progestin address the hormonal pathogenesis of acne, decreasing free testosterone by 40-50% on average.^{65,66} Estrogen also reduces the conversion of testosterone to dihydrotestosterone in the pilosebaceous unit, further decreasing sebum production.

A Cochrane review supports the effectiveness of all COCs for the treatment of acne in women and a few preparations have been approved specifically for acne.^{35,67–70} Trials comparing drospirenone containing COCs to other COCs have generally favored the drospirenone containing COC.^{70–75} In contrast, progestin only contraceptives and long-acting reversible contraceptives are associated with worsening of acne.⁷⁵ A course of three to six months of therapy is typically required for patients to experience the full benefit of treatment with a COC.⁷⁶

Adverse effects and monitoring

The most common side-effect in patients taking COCs is breakthrough bleeding, which is often associated with missed pills. Other common side-effects include nausea and breast tenderness. All of these side-effects have a tendency to resolve over the first 2-3 cycles of use.^{35,77} More serious adverse effects associated with COCs are thromboembolic events. While the risk of venous thromboembolism in reproductive age non-COC users is approximately 2 per 10,000 person years, this rate increases to approximately 6 per 10,000 person years for those on COCs and to approximately 9 per 10,000 person years for drospirenone containing COCs.^{78,79} Due to these risks, the labelling for drospirenone containing COCs includes a warning to limit use to those who also desire a COC for birth control.⁸⁰ However, when counseling patients it is important to keep in mind that the attributable risk for venous thromboembolism is low; in fact, the risk of venous

thromboembolism is higher with pregnancy than COC use.⁷⁹ Similarly, the attributable risk for cardiovascular events (approximately 2 per 10,000 person-years) and ischemic stroke (approximately 1 per 25,000 person-years) are low in otherwise healthy women. In addition, women who take a COC are not at increased risk for cardiovascular disease later in life.^{81–88}

While there is conflicting data on the potential association between COCs and breast cancer, there is compelling evidence that COCs are associated with a significantly reduced risk of colon cancer, uterine cancer, and ovarian cancer. Overall, COCs are associated with a net decrease in cancer risk, including a 29% decreased risk of gynecologic malignancies.^{89,90}

Since drospirenone containing COCs have a mild potassium-sparing diuretic effect, there have been concerns about hyperkalemia with these agents. However, multiple, large retrospective cohort studies of patients prescribed a drospirenone containing COC have found no increased risk of hyperkalemia compared to patients prescribed other COCs.^{60,91,92} In addition, a retrospective study of 5,752 patients taking both spironolactone and drospirenone containing COCs concomitantly found no significant increased risk for hyperkalemia.⁶⁰

ISOTRETINOIN

Isotretinoin is typically started at 0.5mg/kg/day and uptitrated to 1mg/kg/day as tolerated (Table 4).¹⁹ Several alternative dosing approaches have also been proposed. Low dose isotretinoin (e.g. 0.2 to 0.4mg/kg/day) has been demonstrated to have similar effectiveness and reduced side-effects when compared to higher dose regimens, although these studies have been in patients with mild to moderate acne with limited follow-up.^{93–96} There is evidence that higher cumulative doses of isotretinoin are associated with decreased rates of relapse. A prospective study of 180 patients with severe acne found that the relapse rate at 1 year was 26.6% among those who received >220mg/kg cumulative dose compared to 43.8% among those treated with lower doses.⁹⁷ In addition, there have been suggestions that continuing treatment for at least two months after achieving no evidence of activity results in a decreased frequency of relapse.^{95,98}

While isotretinoin is the only acne medication that alters the course of the disease, many patients will have some degree of relapse following discontinuation of treatment, with most relapses occurring within the first 3 years.^{99–101} Younger age at initial treatment and male gender are associated with an increased risk of relapse, with those under 16 years of age having approximately a 25% increased rate of relapse.¹⁰¹ One cohort study found that among those under 16 years of age treated with a course of 120-150mg/kg of isotretinoin, nearly 80% of patients required a second course of therapy within 2 years after completing the first course of isotretinoin.¹⁰²

Adverse effects and monitoring

Almost all patients treated with isotretinoin will experience mucocutaneous dryness, which can typically be managed with liberal emollient use or topical steroids if needed.^{103–105} Xerophthalmia, conjunctivitis, and other ocular complications can occasionally be observed; patients with conditions that can impair corneal wetting (e.g. contact lenses) should be

counseled about these potential side-effects and primary prevention with ocular lubricants should be considered.^{103–107} A randomized trial of 118 patients found omega-3 1g/day reduces mucocutaneous side effects from isotretinoin.¹⁰⁸ Myalgias can be reported in up to a quarter of patients receiving high-dose isotretinoin. Importantly, these myalgias are not associated with decreases in muscle strength or performance.^{103,104,109}

Retinoid embryopathy is a serious and well-documented complication of systemic retinoid exposure during pregnancy, and patients must be enrolled in the iPLEDGE program during treatment.¹¹⁰

While some early reports suggested there may be an association between isotretinoin use and the development of inflammatory bowel disease, subsequent studies controlling for potential confounders such as oral antibiotic use and a recent meta-analysis of six prior studies have not confirmed such a risk.^{111–116} The relationship between depression and the use of isotretinoin is uncertain. A recent meta-analysis found no association between isotretinoin and increased risk of depression and depressive symptoms overall are decreased following treatment.^{117–119} However, there are reports of patients who experience mood changes during treatment with positive dechallenge and rechallenge responses.^{120,121} While isotretinoin is associated with improved mood for the majority of patients as their acne improves, it is sensible to educate the patient and family about depression and to monitor for concerning symptoms during treatment.

Recent evidence suggests that routine monitoring of complete blood count is unwarranted.^{122,123} Mild increases in triglycerides are observed in about a quarter of patients treated with isotretinoin, but severe abnormalities are infrequent and subsequent changes to lipid levels are uncommon once a stable dose has been achieved. A reasonable approach is to check triglycerides and liver enzymes at baseline and two months into treatment, with more frequent monitoring with dose changes or as otherwise clinically indicated.^{123,124}

With respect to the timing of procedural interventions, a recent systematic review found insufficient evidence to support delaying procedures other than mechanical dermabrasion and fully ablative laser treatments.¹²⁵

EMERGING TOPICAL THERAPIES

Topical retinoids, benzoyl peroxide, and topical antibiotics have been a mainstay of the topical management of acne for decades. Novel Food and Drug Administration (FDA) approved topical therapies for acne are needed.^{19,126} Topical medications aiming to suppress sebum production are one emerging approach.¹²⁷ The enzyme stearoyl-CoA desaturase 1 (SCD1) is a potential target for reducing sebum production. Inhibition of SCD1 has been shown to reduce the synthesis of monounsaturated fatty acids and the number of sebaceous glands in mouse skin. Several clinical trials of topical formulations of SCD1 are ongoing. Melanocortin peptide α -melanocyte-stimulating hormone (α -MSH) has demonstrated a sebostrophic effect in mice and an α -MSH mimetic compound is being tested in subjects with acne in a phase 2 study.^{127,128}

Nitric-oxide (NO) releasing particles are under investigation due to their potential to suppress the release of multiple cytokines from human monocytes and keratinocytes and to prevent *C. acnes* induced inflammation.¹²⁹ Two phase 2 studies of the topical NO-releasing drug SB204 found that it significantly reduced non-inflammatory and inflammatory lesion counts in patients with mild, moderate, and severe acne compared to vehicle alone.^{128,130,131}

Finally, a phase 2 study of the anti-androgen cream (cortexolone 17 α -propionate 1%) found improved total and inflammatory lesions counts compared to placebo after 8 weeks of therapy.¹³² Phase 3 studies are ongoing.¹²⁸

LASER AND LIGHT-BASED THERAPIES

Photodynamic therapy

Photodynamic therapy (PDT) is an off-label treatment for acne that involves first applying 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) to the skin, each of which are preferentially absorbed by the pilosebaceous unit.¹³³ Blue light, red light, pulse dye laser (PDL), or intense pulsed light is then used to activate the topical agent to produce photosensitizing porphyrins, which generate free radicals and reactive oxygen species that damage sebaceous glands and result in the destruction of *C. acnes*.^{134,135}

A recent randomized trial evaluating 46 patients treated with either ALA-PDT followed by adapalene 0.1% gel or oral doxycycline 100 mg/daily plus adapalene gel found a greater reduction of inflammatory and total lesion counts in the PDT group at 12 weeks.¹³⁶

However, additional high-quality trials are needed, since most studies of PDT are small, unblinded, and observational with varying treatment protocols.^{19,137}

Other light-based and laser treatments

Since photoexciting porphyrins produced by *C. acnes* could release singlet oxygen species that kill bacteria, devices that emit blue and/or red light (including at-home light emitting diode based devices), have been explored as therapeutic modalities, although the quality of evidence is low to support their efficacy.^{133,134,138–141} Intense pulsed light (IPL) has been explored due to its potential to destroy *C. acnes* and induce thermolysis of blood vessels supplying the sebaceous glands, thereby reducing sebum production.^{142,143} Several small trials assessing the utility of IPL in acne have concluded that IPL (alone or in combination with photopneumatic therapy) may be effective in reducing acne.^{144–146} A number of limited studies have supported the efficacy of the pulsed dye laser (PDL) for treating acne.^{147–152} As PDL preferentially targets oxyhemoglobin and induces photothermolysis of blood vessels, some believe it should be particularly effective in treating inflammatory acne lesions.¹⁵³ Several studies have found the 1450 nm diode laser can improve acne and it has been shown to cause sebaceous gland destruction in a rabbit ear model and in *ex vivo* human skin.^{154–159}

To improve efficacy and reduce side-effects of laser-based treatments, attempts have been made to concentrate the thermal injury to the sebaceous glands while sparing surrounding structures using gold-coated silica and silver microparticles. While a gold-coated silica microparticle suspension is currently marketed in Europe, it is not available in the United

States and two recent trials of a topical silver photoparticle compound in conjunction with 810 nm and 1064 nm lasers did not achieve the primary efficacy endpoints.^{160,161}

DIET AND ACNE

Glycemic index

Since high glycemic-load diets (HGLDs) may increase levels of insulin-like growth factor 1 (IGF-1) activity and activation, thereby inducing proliferation of both keratinocytes and sebocytes as well as stimulating androgen production, some have proposed that HGLDs might be pathogenic in acne.^{162–169} Observational studies have found conflicting results regarding the influence of HGLD and acne.^{170–177} While individual randomized trials have found that a low glycemic-load diet (LGLD) decreases sebum production and reduces acne lesion counts compared to HGLD, a 2015 Cochrane review found insufficient evidence to support LGLD for the management of acne.^{178,182} Additional evidence is needed regarding the impact of LGLD on acne; however, given the low risk and potential health benefits of LGLD (many of the patients in the above trials also experienced weight loss), we feel the practitioner should consider recommending LGLDs as a helpful adjuvant for the treatment of acne.

Milk

Milk consumption, like HGLDs, has been suggested to play a potential role in the pathogenesis of acne by increasing insulin and IGF-1 levels.¹⁶⁴ In addition, it has been noted that milk contains bovine IGF-1, which is able to bind to the human IGF-1 receptor and contains dihydrotestosterone precursors including placenta-derived progesterone, 5 α -pregnanedione, and 5 α -androstanedione that may promote acne.^{166,183,184}

Several retrospective and prospective observational studies have suggested a potential association between dairy consumption and acne.^{185–187} A recent meta-analysis of 14 observational studies found a positive relationship between acne and total milk, low-fat milk, and skim milk intake.¹⁸⁸ This relationship was stronger with low-fat milk and skim milk than whole milk. It has been suggested that the fat-reducing process could enhance the insulin and IGF-1-promoting elements of milk.

Finally, given that whey protein constitutes 20% of protein in cow's milk, its insulin-promoting component could help to explain the possible link between milk and acne.^{164,166,189} A case report of 5 men who developed acne in the setting of whey protein supplement consumption that improved upon discontinuation of the supplement supports this potential association.¹⁸⁹ Of note, a liter of milk contains only about 6g of whey protein, whereas bodybuilders may consume 40-80g of whey daily (equivalent of 6-12 liters of milk).¹⁹⁰ Given how commonly whey protein is used as a nutritional supplement, it is an important exacerbating factor to consider in those with acne. We recommend screening for whey protein supplements and stopping them when acne occurs in those consuming it.

CONCLUSIONS

Although oral antibiotics are the most frequently prescribed agent for moderate to severe acne, their use can be associated with a variety of adverse effects and multiple guidelines recommend limiting their use. Emerging topical therapies, laser and light-based modalities, dietary modification, spironolactone, combined oral contraceptives, and isotretinoin can all be effective therapeutic alternatives in the appropriate clinical context. Careful consideration of these options is an important opportunity to improve antibiotic stewardship and outcomes in patients with acne.

Acknowledgments

Funding Sources: Dr. Barbieri is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number T32-AR-007465 and receives partial salary support through a Pfizer Fellowship grant to the Trustees of the University of Pennsylvania.

REFERENCES

1. Cooper AJ. Systematic review of *Propionibacterium acnes* resistance to systemic antibiotics. *Med J Aust.* 1998; 169(5):259–261. [PubMed: 9762064]
2. Walsh TR, Efthimiou J, Dréno B. Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. *Lancet Infect Dis.* 2016;16(3):e23–33. [PubMed: 26852728]
3. Del Rosso JQ, Zeichner JA. The Clinical Relevance of Antibiotic Resistance: Thirteen Principles That Every Dermatologist Needs to Consider When Prescribing Antibiotic Therapy. *Dermatol Clin.* 2016;34(2):167–173. doi:10.1016/j.det.2015.12.003 [PubMed: 27015776]
4. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant *Propionibacterium acnes* isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. *Br J Dermatol.* 2001;144(2):339–346. [PubMed: 11251569]
5. Delost GR, Delost ME, Armile J, Lloyd J. *Staphylococcus aureus* carriage rates and antibiotic resistance patterns in patients with acne vulgaris. *J Am Acad Dermatol.* 2016;74(4):673–678. [PubMed: 26777099]
6. Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibiotics on the oropharyngeal flora in patients with acne. *Arch Dermatol.* 2003;139(4):467–471. [PubMed: 12707094]
7. Margolis DJ, Fanelli M, Kupperman E, et al. Association of pharyngitis with oral antibiotic use for the treatment of acne: a cross-sectional and prospective cohort study. *Arch Dermatol.* 2012;148(3):326–332. [PubMed: 22105812]
8. Margolis DJ, Bowe WP, Hoffstad O, Berlin JA. Antibiotic treatment of acne may be associated with upper respiratory tract infections. *Arch Dermatol.* 2005;141(9):1132–1136. [PubMed: 16172310]
9. Bowe WP, Hoffstad O, Margolis DJ. Upper respiratory tract infection in household contacts of acne patients. *Dermatology.* 2007;215(3):213–218. [PubMed: 17823518]
10. Mills O, Thornsberry C, Cardin CW, Smiles KA, Leyden JJ. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. *Acta Derm Venereol.* 2002;82(4):260–265. [PubMed: 12361129]
11. Luk N-MT, Hui M, Lee H-CS, et al. Antibiotic-resistant *Propionibacterium acnes* among acne patients in a regional skin centre in Hong Kong. *J Eur Acad Dermatol Venereol JEADV.* 2013;27(1):31–36. [PubMed: 22103749]
12. Dreno B, Thiboutot D, Gollnick H, et al. Antibiotic stewardship in dermatology: limiting antibiotic use in acne. *Eur J Dermatol EJD.* 2014;24(3):330–334. [PubMed: 24721547]
13. Fischer AH, Haskin A, Okoye GA. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. *J Am Acad Dermatol.* 2017;76(2):309–313.e2. [PubMed: 27742173]

14. Dik VK, van Oijen MGH, Smeets HM, Siersema PD. Frequent Use of Antibiotics Is Associated with Colorectal Cancer Risk: Results of a Nested Case-Control Study. *Dig Dis Sci*. 2016;61(1):255–264. [PubMed: 26289256]
15. Adler BL, Kornmehl H, Armstrong AW. Antibiotic Resistance in Acne Treatment. *JAMA Dermatol*. 2017;153(8):810–811. [PubMed: 28636689]
16. Margolis DJ, Fanelli M, Hoffstad O, Lewis JD. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. *Am J Gastroenterol*. 2010;105(12):2610–2616. [PubMed: 20700115]
17. Cao Y, Wu K, Mehta R, et al. Long-term use of antibiotics and risk of colorectal adenoma. *Gut*. 4 2017.
18. Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer. *JAMA*. 2004;291(7):827–835. [PubMed: 14970061]
19. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. *J Am Acad Dermatol*. 2016;74(5):945–973.e33. [PubMed: 26897386]
20. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among us ambulatory care visits, 2010–2011. *JAMA*. 2016;315(17):1864–1873. [PubMed: 27139059]
21. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. *J Am Acad Dermatol*. 2003;49(1 Suppl):S1–37. [PubMed: 12833004]
22. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. *J Am Acad Dermatol*. 2009;60(5 Suppl):S1–50. [PubMed: 19376456]
23. Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. *Pediatrics*. 2006;118(3):1188–1199. [PubMed: 16951015]
24. Dréno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. *Eur J Dermatol EJD*. 2004;14(6):391–399. [PubMed: 15564203]
25. Nast A, Dréno B, Bettoli V, et al. European evidence-based (S3) guidelines for the treatment of acne. *J Eur Acad Dermatol Venereol JEADV*. 2012;26 Suppl 1:1–29.
26. Barbieri JS, Hoffstad O, Margolis DJ. Duration of oral tetracycline-class antibiotic therapy and use of topical retinoids for the treatment of acne among general practitioners (GP): A retrospective cohort study. *J Am Acad Dermatol*. 2016;75(6):1142–1150.e1. [PubMed: 27502311]
27. Barbieri JS, James WD, Margolis DJ. Trends in prescribing behavior of systemic agents used in the treatment of acne among dermatologists and nondermatologists: A retrospective analysis, 2004–2013. *J Am Acad Dermatol*. 2017;77(3):456–463.e4. [PubMed: 28676330]
28. Straight CE, Lee YH, Liu G, Kirby JS. Duration of oral antibiotic therapy for the treatment of adult acne: a retrospective analysis investigating adherence to guideline recommendations and opportunities for cost-savings. *J Am Acad Dermatol*. 2015;72(5):822–827. [PubMed: 25752715]
29. Lee YH, Liu G, Thiboutot DM, Leslie DL, Kirby JS. A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: investigating practice gaps and potential cost-savings. *J Am Acad Dermatol*. 2014;71(1):70–76. [PubMed: 24725476]
30. Centers for Disease Control and Prevention. Outpatient Antibiotic Prescriptions - United States. Annual Report 2013. http://www.cdc.gov/getsmart/community/pdfs/annual-reportsummary_2013.pdf. Accessed September 20, 2016.
31. Khondker L, Khan SI. Acne vulgaris related to androgens - a review. *Mymensingh Med J MMJ*. 2014;23(1):181–185. [PubMed: 24584396]
32. Bergfeld WF. The pathophysiology of acne vulgaris in children and adolescents, Part 1. *Cutis*. 2004;74(2):92–97. [PubMed: 15379361]
33. Tilles G. Acne pathogenesis: history of concepts. *Dermatol Basel Switz*. 2014;229(1):1–46.
34. Kistowska M, Meier B, Proust T, et al. Propionibacterium acnes promotes Th17 and Th17/Th1 responses in acne patients. *J Invest Dermatol*. 2015;135(1):110–118. [PubMed: 25010142]
35. George R, Clarke S, Thiboutot D. Hormonal therapy for acne. *Semin Cutan MedSurg*. 2008;27(3):188–196.

36. Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. *Br J Dermatol.* 1984;111(2):209–214. [PubMed: 6235834]
37. Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. *Br J Dermatol.* 1986;115(2):227–232. [PubMed: 2943311]
38. Hatwal A, Bhatt RP, Agrawal JK, Singh G, Bajpai HS. Spironolactone and cimetidine in treatment of acne. *Acta Derm Venereol.* 1988;68(1):84–87. [PubMed: 2449021]
39. Vaswani N, Pandhi RK. Treatment of acne vulgaris with anti androgens. *Indian J Dermatol Venereol Leprol.* 1990;56(1):34.
40. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. *Fertil Steril.* 1994;61(2):281–287. [PubMed: 8299783]
41. Kriplani A, Thulkar J, Agrawal N, Kulshrestha V, Ammini A.c, Kumar G A comparative study of Diane-35 plus spironolactone and Diane-35 plus finasteride in cases of hirsutism and acne. 2009;7(4):235–241.
42. Hagag P, Steinschneider M, Weiss M. Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome. *J Reprod Med.* 2014;59(9–10):455–463. [PubMed: 25330687]
43. Leelaphiwat S, Jongwutiwes T, Lertvikool S, et al. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. *J Obstet Gynaecol Res.* 2015;41(3):402–410. [PubMed: 25319761]
44. Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review. *Am J Clin Dermatol.* 2 2017.
45. Berardesca E, Gabba P, Ucci G, Borroni G, Rabbiosi G. Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris. *Int J Tissue React.* 1988;10(2):115–119. [PubMed: 2972662]
46. Akamatsu H, Zouboulis CC, Orfanos CE. Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5 alpha-dihydrotestosterone in vitro. *J Invest Dermatol.* 1993;100(5):660–662. [PubMed: 8491989]
47. Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. *Cochrane Database Syst Rev.* 2009; (2):CD000194. [PubMed: 19370553]
48. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. *J Am Acad Dermatol.* 2000;43(3):498–502. [PubMed: 10954662]
49. Charny JW, Choi JK, James WD. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. *Int J Womens Dermatol.* 2017;0(0). [http://www.ijwdonline.org/article/S2352-6475\(16\)30036-3/abstract](http://www.ijwdonline.org/article/S2352-6475(16)30036-3/abstract). Accessed March 23, 2017.
50. Grandhi R, Alikhan A. Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study. *Dermatol Basel Switz.* 5 2017.
51. Isvy-Joubert A, Nguyen J-M, Gaultier A, et al. Adult female acne treated with spironolactone: a retrospective data review of 70 cases. *Eur J Dermatol EJD.* 2017;27(4):393–398. [PubMed: 28862134]
52. Sato K, Matsumoto D, Iizuka F, et al. Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians. *Aesthetic Plast Surg.* 2006;30(6):689–694. [PubMed: 17077951]
53. Park JH, Bienenfeld A, Orlow SJ, Nagler AR. The Use of Hormonal Antiandrogen Therapy in Female Patients with Acne: A 10-Year Retrospective Study. *Am J Clin Dermatol.* 3 2018.
54. Barbieri JS, Choi JK, Mitra N, Margolis DJ. Frequency of Treatment Switching for Spironolactone Compared to Oral Tetracycline-Class Antibiotics for Women With Acne: A Retrospective Cohort Study 2010-2016. *J Drugs Dermatol JDD.* 2018;17(6):632–638. [PubMed: 29879250]
55. Krunic A, Ciurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. *J Am Acad Dermatol.* 2008;58(1):60–62. [PubMed: 17964689]

56. Hughes BR, Cunliffe WJ. Tolerance of spironolactone. *Br J Dermatol*. 1988;118(5):687–691. [PubMed: 2969259]
57. Hecker A, Hasan SH, Neumann F. Disturbances in sexual differentiation of rat foetuses following spironolactone treatment. *Acta Endocrinol (Copenh)*. 1980;95(4):540–545. [PubMed: 7456979]
58. Food and Drug Administration. Aldactone (spironolactone) tablets. Physician Labeling. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/012151s0621bl.pdf. Accessed November 9, 2017.
59. Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. *JAMA Dermatol*. 2015;151(9):941–944. [PubMed: 25796182]
60. Bird ST, Pepe SR, Etminan M, Liu X, Brophy JM, Delaney JA. The association between drospirenone and hyperkalemia: a comparative-safety study. *BMC Clin Pharmacol*. 2011;11:23. [PubMed: 22208934]
61. Shaw JC, White LE. Long-term safety of spironolactone in acne: results of an 8-year followup study. *J Cutan MedSurg*. 2002;6(6):541–545.
62. Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L. Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. *BMJ*. 2012;345:e4447. [PubMed: 22797844]
63. Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M. Spironolactone use and the risk of breast and gynecologic cancers. *Cancer Epidemiol*. 2013;37(6):870–875. [PubMed: 24189467]
64. Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. *Br J Clin Pharmacol*. 2017;83(3):653–663. [PubMed: 27735065]
65. Fotherby K, Caldwell AD. New progestogens in oral contraception. *Contraception*. 1994;49(1):1–32. [PubMed: 8137623]
66. Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME. Effect of low-dose oral contraceptives on androgenic markers and acne. *Contraception*. 1999;60(5):255–262. [PubMed: 10717776]
67. Redmond GP, Olson WH, Lippman JS, Kafrisen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. *Obstet Gynecol*. 1997;89(4):615–622. [PubMed: 9083323]
68. Maloney JM, Dietze P, Watson D, et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. *Obstet Gynecol*. 2008;112(4):773–781. [PubMed: 18827119]
69. Koltun W, Maloney JM, Marr J, Kunz M. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 µg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis. *Eur J Obstet Gynecol Reprod Biol*. 2011;155(2):171–175. [PubMed: 21288628]
70. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. *Cochrane Database Syst Rev*. 2012;(6):CD004425.
71. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. *Cutis*. 2002;69(4 Suppl):2–15.
72. Kelly S, Davies E, Fearn S, et al. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study. *Clin Drug Investig*. 2010;30(5):325–336.
73. Thorneycroft Ian H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. *Cutis*. 2004;74(2):123–130. [PubMed: 15379365]
74. Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. *Eur J Contracept Reprod Health Care Off J Eur Soc Contracept*. 2011;16(6):430–443.

75. Lortscher D, Admani S, Satur N, Eichenfield LF. Hormonal Contraceptives and Acne: A Retrospective Analysis of 2147 Patients. *J Drugs Dermatol JDD*. 2016;15(6):670–674. [PubMed: 27272072]
76. Koo EB, Petersen TD, Kimball AB. Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. *J Am Acad Dermatol*. 2014;71(3):450–459. [PubMed: 24880665]
77. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. *Contraception*. 1995;51(5):283–288. [PubMed: 7628201]
78. de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. *Cochrane Database Syst Rev*. 2014;(3):CD010813. [PubMed: 24590565]
79. Reid RL. Oral contraceptives and venous thromboembolism: pill scares and public health. *J Obstet Gynaecol Can JOGC J Obstet Gynecol Can JOGC*. 2011;33(11):1150–1155.
80. Food and Drug Administration. Yaz (drospirenone/ethinyl estradiol) tablets. Physician Labeling. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021676s012lbl.pdf. Accessed September 17, 2018.
81. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. *BMJ*. 1989;298(6667):165–168. [PubMed: 2493841]
82. Rosenberg L, Palmer JR, Rao RS, Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. *Arch Intern Med*. 2001;161(8):1065–1070. [PubMed: 11322840]
83. Merz CNB, Johnson BD, Berga S, et al. Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. *Fertil Steril*. 2006;85(5):1425–1431. [PubMed: 16600235]
84. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. *N Engl J Med*. 1988;319(20):1313–1317. [PubMed: 3185634]
85. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. *N Engl J Med*. 2012;366(24):2257–2266. [PubMed: 22693997]
86. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. *MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep*. 2016;65(3):1–103.
87. MacClellan LR, Giles W, Cole J, et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. *Stroke*. 2007;38(9):2438–2445. [PubMed: 17690308]
88. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. *JAMA*. 2000;284(1):72–78. [PubMed: 10872016]
89. Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary Hormonal Contraception and the Risk of Breast Cancer. *N Engl J Med*. 2017;377(23):2228–2239. [PubMed: 29211679]
90. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. *BMJ*. 2007;335(7621):651. [PubMed: 17855280]
91. Loughlin J, Seeger JD, Eng PM, et al. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. *Contraception*. 2008;78(5):377–383. [PubMed: 18929734]
92. Schürmann R, Blode H, Benda N, Cronin M, Kufner A. Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. *J Clin Pharmacol*. 2006;46(8):867–875. [PubMed: 16855071]
93. Lee JW, Yoo KH, Park KY, et al. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. *Br J Dermatol*. 2011;164(6):1369–1375. [PubMed: 21114478]
94. Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. *J Am Acad Dermatol*. 2006;54(4):644–646. [PubMed: 16546586]

95. Borghi A, Mantovani L, Minghetti S, Giari S, Virgili A, Bettoli V. Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission. *J Eur Acad Dermatol Venereol JEADV*. 2011;25(9):1094–1098. [PubMed: 21198947]
96. Faghihi G, Mokhtari F, Fard NM, Motamedi N, Hosseini SM. Comparing the Efficacy of Low Dose and Conventional Dose of Oral Isotretinoin in Treatment of Moderate and Severe Acne Vulgaris. *J Res Pharm Pract*. 2017;6(4):233–238. [PubMed: 29417084]
97. Blasiak RC, Stamey CR, Burkhart CN, Lugo-Somolinos A, Morrell DS. High-dose isotretinoin treatment and the rate of retreat, relapse, and adverse effects in patients with acne vulgaris. *JAMA Dermatol*. 2013;149(12):1392–1398. [PubMed: 24173086]
98. Rademaker M Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris. *Int J Dermatol*. 2016;55(5):518–523. [PubMed: 26471145]
99. Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment. *Br J Dermatol*. 1993;129(3):292–296. [PubMed: 8286227]
100. White GM, Chen W, Yao J, Wolde-Tsadik G. Recurrence rates after the first course of isotretinoin. *Arch Dermatol*. 1998;134(3):376–378. [PubMed: 9521042]
101. Azoulay L, Oraichi D, Berard A. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. *Br J Dermatol*. 2007;157(6):1240–1248. [PubMed: 17970803]
102. Leyden JJ. Oral isotretinoin. How can we treat difficult acne patients? *Dermatol Basel Switz*. 1997;195 Suppl 1:29–33; discussion 38–40.
103. Park H, Skopit S. Safety Considerations and Monitoring in Patients Treated with Systemic Medications for Acne. *Dermatol Clin*. 2016;34(2):185–193. [PubMed: 27015778]
104. Rademaker M Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. *Australas J Dermatol*. 2010;51(4):248–253. [PubMed: 21198520]
105. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. *J Am Acad Dermatol*. 2001;45(5):S150–157. [PubMed: 11606947]
106. Caffery BE, Josephson JE. Ocular side effects of isotretinoin therapy. *J Am Optom Assoc*. 1988;59(3):221–224. [PubMed: 3258326]
107. Neudorfer M, Goldshtein I, Shamai-Lubovitz O, Chodick G, Dadon Y, Shalev V. Ocular adverse effects of systemic treatment with isotretinoin. *Arch Dermatol*. 2012;148(7):803–808. [PubMed: 22508771]
108. Mirnezami M, Rahimi H. Is Oral Omega-3 Effective in Reducing Mucocutaneous Side Effects of Isotretinoin in Patients with Acne Vulgaris? *Dermatology Research and Practice*. <https://www.hindawi.com/journals/drj/2018/6974045/abs/>. Published 2018. Accessed August 3, 2018.
109. Yildizgören MT, Rifaio lu EN, Demirkapi M, et al. Isotretinoin treatment in patients with acne vulgaris: does it impact muscle strength, fatigue, and endurance? *Cutis*. 2015;96(1):33–36. [PubMed: 26244352]
110. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. *N Engl J Med*. 1985;313(14):837–841. [PubMed: 3162101]
111. Crockett SD, Porter CQ, Martin CF, Sandler RS, Kappelman MD. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. *Am J Gastroenterol*. 2010;105(9):1986–1993. [PubMed: 20354506]
112. Bernstein CN, Nugent Z, Longobardi T, Blanchard JF. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. *Am J Gastroenterol*. 2009;104(11):2774–2778. [PubMed: 19623167]
113. Etminan M, Bird ST, Delaney JA, Bressler B, Brophy JM. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. *JAMA Dermatol*. 2013;149(2):216–220. [PubMed: 23426479]
114. Alhusayen RO, Juurlink DN, Mamdani MM, et al. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. *J Invest Dermatol*. 2013;133(4):907–912. [PubMed: 23096714]
115. Rashtak S, Khaleghi S, Pittelkow MR, Larson JJ, Lahr BD, Murray JA. Isotretinoin exposure and risk of inflammatory bowel disease. *JAMA Dermatol*. 2014;150(12):1322–1326. [PubMed: 25207875]

116. Lee SY, Jamal MM, Nguyen ET, Bechtold ML, Nguyen DL. Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis. *Eur J Gastroenterol Hepatol*. 2016;28(2):210–216. [PubMed: 26545085]
117. Huang Y-C, Cheng Y-C. Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis. *J Am Acad Dermatol*. 2017;76(6):1068–1076.e9. [PubMed: 28291553]
118. Sundström A, Alfredsson L, Sjölin-Forsberg G, Gerdén B, Bergman U, Jokinen J. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. *BMJ*. 2010;341:c5812. [PubMed: 21071484]
119. Halvorsen JA, Stern RS, Dalgard F, Thoresen M, Bjertness E, Lien L. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. *J Invest Dermatol*. 2011;131(2):363–370. [PubMed: 20844551]
120. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. *J Am Acad Dermatol*. 2001;45(4):515–519. [PubMed: 11568740]
121. Bremner JD, Shearer KD, McCaffery PJ. Retinoic acid and affective disorders: the evidence for an association. *J Clin Psychiatry*. 2012;73(1):37–50.
122. Lee YH, Scharnitz TP, Muscat J, Chen A, Gupta-Elera G, Kirby JS. Laboratory Monitoring During Isotretinoin Therapy for Acne: A Systematic Review and Meta-analysis. *JAMA Dermatol*. 2016;152(1):35–44. doi:10.1001/jamadermatol.2015.3091 [PubMed: 26630323]
123. Hansen TJ, Lucking S, Miller JJ, Kirby JS, Thiboutot DM, Zaenglein AL. Standardized laboratory monitoring with use of isotretinoin in acne. *J Am Acad Dermatol*. 2016;75(2):323–328. [PubMed: 27189824]
124. Shinkai K, McMichael A, Linos E. Isotretinoin Laboratory Test Monitoring--A Call to Decrease Testing in an Era of High-Value, Cost-Conscious Care. *JAMA Dermatol*. 2016;152(1):17–19. [PubMed: 26629966]
125. Spring LK, Krakowski AC, Alam M, et al. Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations. *JAMA Dermatol*. 2017;153(8):802–809. [PubMed: 28658462]
126. Nast A, Dréno B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. *J Eur Acad Dermatol Venereol JEADV*. 2016;30(8):1261–1268. [PubMed: 27514932]
127. Zouboulis CC, Dessinioti C, Tsatsou F, Gollnick HPM. Anti-acne drugs in phase 1 and 2 clinical trials. *Expert Opin Investig Drugs*. 2017;26(7):813–823.
128. Stein Gold LF, Alexis AF, Harper JC, Tan JK. Advances in Acne and Rosacea Therapy. *Semin Cutan Med Surg*. 2018;37(3):S63–S66. [PubMed: 30192344]
129. Qin M, Landriscina A, Rosen JM, et al. Nitric Oxide-Releasing Nanoparticles Prevent *Propionibacterium acnes*-Induced Inflammation by Both Clearing the Organism and Inhibiting Microbial Stimulation of the Innate Immune Response. *J Invest Dermatol*. 2015;135(11):2723–2731. [PubMed: 26172313]
130. Baldwin H, Blanco D, McKeever C, et al. Results of a Phase 2 Efficacy and Safety Study with SB204, an Investigational Topical Nitric Oxide-releasing Drug for the Treatment of Acne Vulgaris. *J Clin Aesthetic Dermatol*. 2016;9(8):12–18.
131. Eichenfield LF, Gold LS, Nahm WK, Cook-Bolden FE, Pariser DM. Results of a Phase 2, Randomized, Vehicle-Controlled Study Evaluating the Efficacy, Tolerability, and Safety of Daily or Twice Daily SB204 for the Treatment of Acne Vulgaris. *J Drugs Dermatol JDD*. 2016;15(12):1496–15027. [PubMed: 28095573]
132. Trifu V, Tiplica G-S, Naumescu E, Zalupca L, Moro L, Celasco G. Cortexolone 17 α -propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. *Br J Dermatol*. 2011;165(1):177–183. [PubMed: 21428978]
133. Nestor MS, Swenson N, Macri A. Physical Modalities (Devices) in the Management of Acne. *Dermatol Clin*. 2016;34(2):215–223. [PubMed: 27015782]
134. Laser Alexiades M. and light-based treatments of acne and acne scarring. *Clin Dermatol*. 2017;35(2):183–189. [PubMed: 28274357]

135. Das S, Reynolds RV. Recent advances in acne pathogenesis: implications for therapy. *Am J Clin Dermatol*. 2014;15(6):479–488. [PubMed: 25388823]
136. Nicklas C, Rubio R, Cárdenas C, Hasson A. Comparison of efficacy of aminolaevulinic acid photodynamic therapy vs. adapalene gel plus oral doxycycline for treatment of moderate acne vulgaris-A simple, blind, randomized, and controlled trial. *Photodermatol Photoimmunol Photomed*. 7 2018.
137. Barbaric J, Abbott R, Posadzki P, et al. Light therapies for acne. *Cochrane Database Syst Rev*. 2016;9:CD007917. [PubMed: 27670126]
138. Kawada A, Aragane Y, Kameyama H, Sangen Y, Tezuka T. Acne phototherapy with a high-intensity, enhanced, narrow-band, blue light source: an open study and in vitro investigation. *J Dermatol Sci*. 2002;30(2):129–135. [PubMed: 12413768]
139. Omi T, Bjerring P, Sato S, Kawana S, Hankins RW, Honda M. 420 nm intense continuous light therapy for acne. *J Cosmet Laser Ther Off Publ Eur Soc Laser Dermatol*. 2004;6(3):156–162.
140. Papageorgiou P, Katsambas A, Chu A. Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris. *Br J Dermatol*. 2000;142(5):973–978. [PubMed: 10809858]
141. Goldberg DJ, Russell BA. Combination blue (415 nm) and red (633 nm) LED phototherapy in the treatment of mild to severe acne vulgaris. *J Cosmet Laser Ther Off Publ Eur Soc Laser Dermatol*. 2006;8(2):71–75.
142. Gold MH. Acne vulgaris: lasers, light sources and photodynamic therapy--an update 2007. *Expert Rev Anti Infect Ther*. 2007;5(6):1059–1069. [PubMed: 18039088]
143. Babilas P, Schreml S, Szeimies R-M, Landthaler M. Intense pulsed light (IPL): a review. *Lasers Surg Med*. 2010;42(2):93–104. [PubMed: 20166155]
144. Elman M, Lask G. The role of pulsed light and heat energy (LHE) in acne clearance. *J Cosmet Laser Ther Off Publ Eur Soc Laser Dermatol*. 2004;6(2):91–95.
145. Kawana S, Tachihara R, Kato T, Omi T. Effect of smooth pulsed light at 400 to 700 and 870 to 1,200 nm for acne vulgaris in Asian skin. *Dermatol Surg Off Publ Am Soc Dermatol Surg Al*. 2010;36(1):52–57.
146. Wanitphakdeedecha R, Tanzi EL, Alster TS. Photopneumatic therapy for the treatment of acne. *J Drugs Dermatol JDD*. 2009;8(3):239–241. [PubMed: 19271370]
147. Chang S-E, Ahn S-J, Rhee D-Y, et al. Treatment of facial acne papules and pustules in Korean patients using an intense pulsed light device equipped with a 530- to 750-nm filter. *Dermatol Surg Off Publ Am Soc Dermatol Surg Al*. 2007;33(6):676–679.
148. Harto A, García-Morales I, Belmar P, Jaén P. [Pulsed dye laser treatment of acne. Study of clinical efficacy and mechanism of action]. *Actas Dermosifiliogr*. 2007;98(6):415–419. [PubMed: 17663931]
149. Karsai S, Schmitt L, Raulin C. The pulsed-dye laser as an adjuvant treatment modality in acne vulgaris: a randomized controlled single-blinded trial. *Br J Dermatol*. 2010;163(2):395–401. [PubMed: 20394631]
150. Leheta TM. Role of the 585-nm pulsed dye laser in the treatment of acne in comparison with other topical therapeutic modalities. *J Cosmet Laser Ther Off Publ Eur Soc Laser Dermatol*. 2009;11(2):118–124.
151. Sami NA, Attia AT, Badawi AM. Phototherapy in the treatment of acne vulgaris. *J Drugs Dermatol JDD*. 2008;7(7):627–632. [PubMed: 18664153]
152. Seaton ED, Charakida A, Mouser PE, Grace I, Clement RM, Chu AC. Pulsed-dye laser treatment for inflammatory acne vulgaris: randomised controlled trial. *Lancet Lond Engl*. 2003;362(9393):1347–1352.
153. Omi T, Kawana S, Sato S, et al. Cutaneous immunological activation elicited by a low-fluence pulsed dye laser. *Br J Dermatol*. 2005;153 Suppl 2:57–62. [PubMed: 16280023]
154. Bernstein EF. Double-pass, low-fluence laser treatment using a large spot-size 1,450 nm laser improves acne. *Lasers Surg Med*. 2009;41(2):116–121. [PubMed: 19226573]
155. Darné S, Hiscutt EL, Seukeran DC. Evaluation of the clinical efficacy of the 1,450 nm laser in acne vulgaris: a randomized split-face, investigator-blinded clinical trial. *Br J Dermatol*. 2011;165(6):1256–1262. [PubMed: 21910712]

156. Friedman PM, Jih MH, Kimyai-Asadi A, Goldberg LH. Treatment of inflammatory facial acne vulgaris with the 1450-nm diode laser: a pilot study. *Dermatol Surg Off Publ Am Soc Dermatol Surg Al.* 2004;30(2 Pt 1):147–151.
157. Jih MH, Friedman PM, Goldberg LH, Robles M, Glaich AS, Kimyai-Asadi A. The 1450-nm diode laser for facial inflammatory acne vulgaris: dose-response and 12-month follow-up study. *J Am Acad Dermatol.* 2006;55(1):80–87. [PubMed: 16781297]
158. Noborio R, Nishida E, Morita A. Clinical effect of low-energy double-pass 1450 nm laser treatment for acne in Asians. *Photodermatol Photoimmunol Photomed.* 2009;25(1):3–7. [PubMed: 19152509]
159. Paithankar DY, Ross EV, Saleh BA, Blair MA, Graham BS. Acne treatment with a 1,450 nm wavelength laser and cryogen spray cooling. *Lasers Surg Med.* 2002;31(2):106–114. [PubMed: 12210594]
160. Paithankar DY, Sakamoto FH, Farinelli WA, et al. Acne Treatment Based on Selective Photothermolysis of Sebaceous Follicles with Topically Delivered Light-Absorbing Gold Microparticles. *J Invest Dermatol.* 2015;135(7):1727–1734. [PubMed: 25748556]
161. Sienna Biopharmaceuticals Announces Pivotal Trials with SNA-001 in Acne Did Not Meet Primary and Secondary Endpoints. Sienna Biopharmaceuticals <https://investors.siennabio.com/news-releases/news-release-details/sienna-biopharmaceuticals-announces-pivotal-trials-sna-001-acne>. Accessed August 5, 2018.
162. Cordain L, Lindeberg S, Hurtado M, Hill K, Eaton SB, Brand-Miller J. Acne vulgaris: a disease of Western civilization. *Arch Dermatol.* 2002;138(12):1584–1590. [PubMed: 12472346]
163. Berra B, Rizzo AM. Glycemic index, glycemic load, wellness and beauty: the state of the art. *Clin Dermatol.* 2009;27(2):230–235. [PubMed: 19168005]
164. Melnik BC, Schmitz G. Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris. *Exp Dermatol.* 2009;18(10):833–841. [PubMed: 19709092]
165. Taylor M, Gonzalez M, Porter R. Pathways to inflammation: acne pathophysiology. *Eur J Dermatol EJD.* 2011;21(3):323–333. [PubMed: 21609898]
166. Bronsnick T, Murzaku EC, Rao BK. Diet in dermatology: Part I. Atopic dermatitis, acne, and nonmelanoma skin cancer. *J Am Acad Dermatol.* 2014;71(6):1039e1–1039.e12. [PubMed: 25454036]
167. Kurokawa I, Danby FW, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. *Exp Dermatol.* 2009;18(10):821–832. [PubMed: 19555434]
168. Danby FW. Nutrition and acne. *Clin Dermatol.* 2010;28(6):598–604. [PubMed: 21034984]
169. Cordain L. Implications for the role of diet in acne. *Semin Cutan Med Surg.* 2005;24(2):84–91. [PubMed: 16092796]
170. Burris J, Rietkerk W, Woolf K. Relationships of self-reported dietary factors and perceived acne severity in a cohort of New York young adults. *J Acad Nutr Diet.* 2014;114(3):384–392. [PubMed: 24412232]
171. Ismail NH, Manaf ZA, Azizan NZ. High glycemic load diet, milk and ice cream consumption are related to acne vulgaris in Malaysian young adults: a case control study. *BMC Dermatol.* 2012;12:13. [PubMed: 22898209]
172. Skroza N, Tolino E, Semyonov L, et al. Mediterranean diet and familial dysmetabolism as factors influencing the development of acne. *Scand J Public Health.* 2012;40(5):466–474. [PubMed: 22833557]
173. Veith WB, Silverberg NB. The association of acne vulgaris with diet. *Cutis.* 2011;88(2):84–91. [PubMed: 21916275]
174. Çerman AA, Akta E, Altunay iK, Arıcı JE, Tulunay A, Ozturk FY. Dietary glycemic factors, insulin resistance, and adiponectin levels in acne vulgaris. *J Am Acad Dermatol.* 2016;75(1):155–162. [PubMed: 27061046]
175. Kaymak Y, Adisen E, Ilter N, Bideci A, Gurler D, Celik B. Dietary glycemic index and glucose, insulin, insulin-like growth factor-I, insulin-like growth factor binding protein 3, and leptin levels in patients with acne. *J Am Acad Dermatol.* 2007;57(5):819–823. [PubMed: 17655968]

176. Reynolds RC, Lee S, Choi JYJ, et al. Effect of the glycemic index of carbohydrates on Acne vulgaris. *Nutrients*. 2010;2(10):1060–1072. [PubMed: 22253996]
177. LaRosa CL, Quach KA, Koons K, et al. Consumption of dairy in teenagers with and without acne. *J Am Acad Dermatol*. 2016;75(2):318–322. [PubMed: 27241803]
178. Cao H, Yang G, Wang Y, et al. Complementary therapies for acne vulgaris. *Cochrane Database Syst Rev*. 2015;1:CD009436. [PubMed: 25597924]
179. Kwon HH, Yoon JY, Hong JS, Jung JY, Park MS, Suh DH. Clinical and histological effect of a low glycaemic load diet in treatment of acne vulgaris in Korean patients: a randomized, controlled trial. *Acta Derm Venereol*. 2012;92(3):241–246. [PubMed: 22678562]
180. Smith RN, Braue A, Varigos GA, Mann NJ. The effect of a low glycemic load diet on acne vulgaris and the fatty acid composition of skin surface triglycerides. *J Dermatol Sci*. 2008;50(1):41–52. [PubMed: 18178063]
181. Smith RN, Mann NJ, Braue A, Makelainen H, Varigos GA. A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial. *Am J Clin Nutr*. 2007;86(1):107–115. [PubMed: 17616769]
182. Smith RN, Mann NJ, Braue A, Makelainen H, Varigos GA. The effect of a high-protein, low glycemic-load diet versus a conventional, high glycemic-load diet on biochemical parameters associated with acne vulgaris: a randomized, investigator-masked, controlled trial. *J Am Acad Dermatol*. 2007;57(2):247–256. [PubMed: 17448569]
183. Melnik B Milk consumption: aggravating factor of acne and promoter of chronic diseases of Western societies. *J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG*. 2009;7(4):364–370.
184. Danby FW. Acne and milk, the diet myth, and beyond. *J Am Acad Dermatol*. 2005;52(2):360–362. [PubMed: 15692488]
185. Adebamowo CA, Spiegelman D, Danby FW, Frazier AL, Willett WC, Holmes MD. High school dietary dairy intake and teenage acne. *J Am Acad Dermatol*. 2005;52(2):207–214. [PubMed: 15692464]
186. Adebamowo CA, Spiegelman D, Berkey CS, et al. Milk consumption and acne in adolescent girls. *Dermatol Online J*. 2006;12(4):1.
187. Adebamowo CA, Spiegelman D, Berkey CS, et al. Milk consumption and acne in teenaged boys. *J Am Acad Dermatol*. 2008;58(5):787–793. [PubMed: 18194824]
188. Aghasi M, Golzarand M, Shab-Bidar S, Aminianfar A, Omidian M, Taheri F. Dairy intake and acne development: A meta-analysis of observational studies. *Clin Nutr Edinb Scotl*. 5 2018.
189. Silverberg NB. Whey protein precipitating moderate to severe acne flares in 5 teenaged athletes. *Cutis*. 2012;90(2):70–72. [PubMed: 22988649]
190. Van Mol P Milk And Bodybuilding - Do They Mix? [Bodybuilding.com. https://www.bodybuilding.com/content/milk-and-bodybuilding-do-they-mix.html](https://www.bodybuilding.com/content/milk-and-bodybuilding-do-they-mix.html). Published March 15, 2001. Accessed August 5, 2018.

Table 1:

Summary of recent observational studies supporting the efficacy of spironolactone for the treatment of women with acne

Study	Study Size	Key Findings
Charny 2017 ⁴⁹	110	84% of those treated with spironolactone 100mg/day showed initial improvement, with 40% clearing completely. An additional 32 patients improved or cleared by increasing the dose to 150mg/day and another 13 improved or cleared at 200mg/day.
Grandhi 2017 ⁵⁰	400	86% of patients reported improvement, with only 4% experiencing any side effects.
Isvy-Joubert 2017 ⁵¹	70	In a population in which 60% had previously relapsed after treatment with isotretinoin, 71% of patients had a good clinical response to spironolactone, with a median time to response of 6 months.
Park 2018 ⁵³	672	The mean cumulative antibiotic duration for women who received either a combined oral contraceptive or spironolactone was 83.4 fewer days than for those who did not receive either therapy, after controlling for age and acne type.
Barbieri 2018 ⁵⁴	38,298	The rate of switching to another systemic agent within the first year of therapy was similar between those who initially received spironolactone (14.4%) and those who initially received antibiotics (13.4%), suggesting that spironolactone may have similar clinical effectiveness to oral antibiotics for women with acne.

Table 2:

Suggested dosing, contraindications, side-effects, monitoring, and pregnancy and lactation information for spironolactone

Dosing	25-200mg daily, typically starting 100mg daily in the evening
Contraindications	Significant renal impairment, hyperkalemia (or medications known to increase serum potassium such as trimethoprim or ACE inhibitors), Addison disease
Side-effects	Menstrual irregularities, breast tenderness, dizziness, nausea, headache, polyuria, fatigue
Monitoring	Routine monitoring is not required in young women without hypertension, renal, or cardiac disease.
Pregnancy category	C
Nursing	Compatible with breastfeeding; risk to infant is minimal

Table 3:

Suggested dosing, contraindications, side-effects, monitoring, and pregnancy and lactation information for combined oral contraceptives used in acne

Dosing	Quick start (preferred): Begin on the day given prescription (as long as pregnancy is reasonably excluded) Sunday start: Begin on the first Sunday after period Combined oral contraceptives approved for acne: ethinyl estradiol 20/30/35 mcg/norethindrone 1 mg, ethinyl estradiol 35 mcg/norgestimate 180/215/250 mcg, and ethinyl estradiol 20 mcg/drospirenone 3 mg
Contraindications	Pregnancy, age >35 years and smoking >15 cigarettes per day, multiple risk factors for CAD, hypertension (>160mmHg systolic or >100mmHg diastolic), VTE, known thrombogenic mutations, history of stroke, complicated valvular heart disease, systemic lupus erythematosus, migraine with aura at any age, breast cancer, cirrhosis, hepatocellular adenoma or malignant hepatoma. Renal insufficiency or hepatic dysfunction for drospirenone containing combined oral contraceptives.
Side-effects	Breakthrough bleeding, nausea, breast tenderness. Increased risk of thromboembolic events (attributable risk low), increased risk of breast cancer (decreased risk of gynecologic malignancies overall)
Monitoring	Blood pressure, routine gynecologic screening
Pregnancy category	X
Nursing	Compatible with breastfeeding (American Academy of Pediatrics)

Table 4:

Suggested dosing, contraindications, side-effects, monitoring, and pregnancy and lactation information for isotretinoin

Dosing	0.2-1.0mg/kg/day, typically starting at 40mg/day if more mild to moderate facial disease. Starting at 20mg/day if severe truncal disease may avoid flares. Increase the dose monthly as patient tolerates with respect to side-effects.
Contraindications	Pregnancy, prior hypersensitivity reaction.
Side-effects	Chelitis, epistaxis, ocular complaints, photosensitivity, muscle aches, skin fragility, fatigue, mood changes, periungual granulomas, increased triglycerides, liver abnormalities.
Monitoring	Pregnancy testing every 30 days (for women). Liver function testing and triglycerides at baseline and at 2 months if no other clinical reasons. More frequent monitoring should be considered with dose changes and in those at risk of complications. Routine CBC monitoring is unwarranted. Engage patient's family or friends to assist patient in monitoring for depression.
Pregnancy category	X, patients must be enrolled in iPLEDGE
Nursing	Not yet determined